Baseline characteristics of the HARVEST-Malmö cohort, the GREAT Network Rome cohort and the pooled cohort
| HARVEST-Malmö N=322 | GREAT Network Rome N=208 | Pooled cohort N=530 | P value | |
| Demographics | ||||
| Age (years) | 75.1±11.1 | 78.5±9.9 | 76.4±10.7 | <0.001 |
| Female sex (%) | 97 (30.1) | 114 (54.8) | 211 (39.8) | <0.001 |
| Smoking (%) | 38 (11.8) | 29 (13.9) | 67 (12.6) | 0.450 |
| Clinical profile, n (%) | ||||
| Systolic blood pressure (mm Hg) | 137.3±27.5 | 150.7±33.7 | 142.3±30.8 | <0.001 |
| Diastolic blood pressure (mm Hg) | 73.6±12.6 | 81.4±16.8 | 77.0±14.9 | <0.001 |
| Ejection fraction (%) | 38 (24–52) | 40 (27–50) | 40 (25–50) | 0.036 |
| Medical history, n (%) | ||||
| Diabetes mellitus | 119 (37.0) | 75 (36.1) | 194 (36.6) | 0.720 |
| Prior heart failure | 200 (62.1) | 85 (40.9) | 285 (53.8) | <0.001 |
| Prevalent atrial fibrillation | 153 (47.5) | 96 (46.2) | 249 (47.0) | 0.762 |
| Medication, n (%) | ||||
| ACE inhibitors/ARB | 251 (77.9) | 109 (52.4) | 360 (67.9) | <0.001 |
| Beta-blockers | 279 (86.6) | 101 (48.6) | 380 (71.7) | <0.001 |
| Diuretics | 306 (95.0) | 132 (63.5) | 438 (82.6) | <0.001 |
| Laboratory | ||||
| Bio-ADM (pg/mL) | 39.6 (25.6–64.5) | 24.6 (9.5–48.4) | 34.6 (18.7–59.3) | <0.001 |
| penKid (pmol/L) | 85.3 (62.8–118.4) | 109.5 (81.7–168.5) | 91.8 (67.9–135.9) | <0.001 |
| BNP (pg/mL) | – | 756 (366–1452) | – | – |
| NT-proBNP (pg/mL) | 4096 (2212–8645) | 7811 (2038–10851) | – | – |
| Creatinine (mg/dL) admission | 1.32±0.64 | 1.44±0.91 | 1.37±0.76 | 0.069 |
| Creatinine (mg/dL) after 48 hours | 1.35±0.64 | 1.53±1.0 | 1.42±0.81 | 0.016 |
| Potassium (mmol/L) | 3.8±0.5 | 4.3±0.6 | 4.0±0.6 | <0.001 |
| Sodium (mmol/L) | 140.5±3.3 | 137.3±5.9 | 139.2±4.7 | <0.001 |
| Haemoglobin (g/L) | 127.6±18.3 | 123.2±24.8 | 125.9±21.2 | 0.019 |
| Outcomes | ||||
| Peripheral oedema (n (%)) | 215 (58.0) | 145 (59.2) | 338 (63.4) | 0.004 |
| WRF (n (%)) | 30 (8.1) | 37 (20.7) | 67 (14.3) | <0.001 |
| In-hospital mortality (n (%)) | 7 (1.9) | 17 (8.2) | 24 (5.1) | <0.001 |
| 1-year mortality (n (%)) | 50 (17.2) | – | – | – |
| Rehospitalisation (n (%)) | 188 (66.2) | – | – | – |
| Length of hospital stay (days) | 7 (4–9) | 6 (3–8) | 6 (4–9) | 0.320 |
Continuous data presented as mean±SD or median (Q1–Q3), depending on distribution.
ARB, angiotensin receptor blocker;BNP, B-type natriuretic peptide;CXR, chest X-ray;HARVEST, HeArt and bRain failure inVESTigation trial; NT-proBNP, N-terminal proBNP;bio-ADM, bioactive adrenomedullin; penKid, proenkephalin A 119–159.